Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
Authors:
Open Access
- 24 June 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1) , e000804
Abstract
Background Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose dependence and the mechanisms mediating this dose dependence are not well understood. Methods To explore this apparent contradiction, we investigated how the initial dose of oncolytic myxoma virus affected the subsequent ability of treatment to alter the immunological status of tumors as well as synergize with programmed cell death protein 1 (PD1) blockade. Results Our results indicate that, due to viral self-amplification in vivo, the overall load of myxoma virus rapidly normalizes within treated tumors despite up to 3-log differences in inoculating dose. Because of this, therapeutic efficacy in the absence of checkpoint blockade is largely dose independent. Despite this rapid normalization, however, treatment with high or low doses of myxoma virus induces distinct immunological changes within treated tumors. Critically, these changes appear to be durably programmed based on the initial oncolytic dose with low-dose treatment failing to induce immunological improvements despite rapidly achieving equivalent viral burdens. Finally, due to the distinct immunological profiles induced by high and low myxoma virus doses, oncolytic efficacy resulting from combination with PD1 blockade therapy displays a strong dose dependence. Conclusions Taken together, these data suggest that the ability of oncolytic myxoma virus to immunologically reprogram treated tumors is dependent on initial viral dose. Additionally, this work could provide a possible mechanistic explanation for clinical results observed with other oncolytic viruses.Keywords
Funding Information
- American Cancer Society (RSG-17-047-01-MPC)
- NIH (R01CA194090, R21AI142387)
This publication has 21 references indexed in Scilit:
- Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?OncoImmunology, 2019
- A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)Journal for ImmunoTherapy of Cancer, 2019
- Emerging strategies for combination checkpoint modulators in cancer immunotherapyJournal of Clinical Investigation, 2018
- Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cellsScience Immunology, 2017
- Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myelomaLeukemia, 2017
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNature Medicine, 2013
- VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 SignalingMolecular Therapy, 2011
- Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaGene Therapy, 2009
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and ReplicationClinical Cancer Research, 2009
- A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant SettingMolecular Therapy, 2004